Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Avecho Biotechnology Limited ( (AU:AVE) ) just unveiled an announcement.
Avecho Biotechnology Limited has made significant progress in its Phase III clinical trial for a CBD TPM soft-gel capsule aimed at treating insomnia, with 160 patients dosed and interim results expected in the first half of 2026. The company completed a $2.5 million capital raise to accelerate manufacturing and regulatory preparations for a Therapeutic Goods Administration submission. This trial, in collaboration with Sandoz AG, positions Avecho to potentially introduce the first over-the-counter CBD insomnia treatment in Australia, while also exploring international licensing opportunities.
More about Avecho Biotechnology Limited
Avecho Biotechnology Limited develops and commercializes innovative human and animal health products using its proprietary drug delivery system called Tocopheryl Phosphate Mixture (TPM®). TPM® is derived from Vitamin E and enhances the solubility and absorption of drugs and nutrients. Avecho’s lead asset is a CBD TPM soft-gel capsule, currently in Phase III clinical development for insomnia treatment.
Current Market Cap: A$19.04M
See more insights into AVE stock on TipRanks’ Stock Analysis page.